Literature DB >> 9052572

Current controversies in the management of aortoiliac occlusive disease.

D C Brewster1.   

Abstract

The numerous options currently available for treatment of aortoiliac occlusive disease have led to considerable controversy in regard to the optimal method of revascularization in such patients. Differences of opinion exist not only with respect to certain technical aspects of direct anatomic aortic reconstruction, which has traditionally been regarded as the "gold standard" treatment, but even more importantly as to whether alternative methods including a variety of catheter-based endoluminal therapies and extraanatomic grafts may offer nearly equivalent results with less risk and possible cost advantages. Although little truly definitive data is available, a review of published information can help clarify many of these management dilemmas. In the final analysis, the various methods may not be as competitive with one another as first seems apparent. Each has its own specific advantages and disadvantages and when used, in appropriate circumstances can provide excellent results. Indeed, it is this broad spectrum of options that can be matched to each patient's own unique anatomic and risk characteristics that make treatment of aortoiliac disease one of the most successful areas of contemporary vascular surgery practice.

Entities:  

Mesh:

Year:  1997        PMID: 9052572     DOI: 10.1016/s0741-5214(97)70359-8

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  16 in total

Review 1.  [Tissue engineering of vascular prostheses].

Authors:  B H Walpoth; M Möller
Journal:  Chirurg       Date:  2011-04       Impact factor: 0.955

2.  Platform technologies for decellularization, tunic-specific cell seeding, and in vitro conditioning of extended length, small diameter vascular grafts.

Authors:  George Fercana; Devon Bowser; Margarita Portilla; Eugene M Langan; Christopher G Carsten; David L Cull; Leslie N Sierad; Dan T Simionescu
Journal:  Tissue Eng Part C Methods       Date:  2014-09-29       Impact factor: 3.056

3.  Videoendoscopically assisted combined retroperitoneal and pelvic extraperitoneal approach for aortoiliac occlusive disease.

Authors:  P K Chowbey; R Panse; A Sharma; R Khullar; V Soni; M Baijal
Journal:  Surg Endosc       Date:  2005-07-28       Impact factor: 4.584

4.  Retroperitoneal approach via paramedian incision for aortoiliac occlusive disease.

Authors:  Bilgin Emrecan; Gokhan Onem; Erkin Ocak; Murat Arslan; Baki Yagci; Ahmet Baltalarli; Beyza Akdag
Journal:  Tex Heart Inst J       Date:  2010

5.  Critical Limb Ischemia.

Authors:  David L. Dawson; Ryan T. Hagino
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-06

6.  The performance of cross-linked acellular arterial scaffolds as vascular grafts; pre-clinical testing in direct and isolation loop circulatory models.

Authors:  Timothy Pennel; George Fercana; Deon Bezuidenhout; Agneta Simionescu; Ting-Hsien Chuang; Peter Zilla; Dan Simionescu
Journal:  Biomaterials       Date:  2014-05-09       Impact factor: 12.479

Review 7.  [Surgical management of peripheral arterial disease. Operative methods and results].

Authors:  B Wulff; T Jungbluth; H Esnaashari; C Franke; H-P Bruch
Journal:  Radiologe       Date:  2006-11       Impact factor: 0.635

8.  Endovascular reconstruction of the aortic bifurcation in patients with Leriche syndrome.

Authors:  Hans Krankenberg; Michael Schlüter; Carsten Schwencke; Dirk Walter; Andrea Pascotto; Jörn Sandstede; Thilo Tübler
Journal:  Clin Res Cardiol       Date:  2009-08-14       Impact factor: 5.460

9.  Ten year outcomes after bypass surgery in aortoiliac occlusive disease.

Authors:  Gwan-Chul Lee; Shin-Seok Yang; Keun-Myoung Park; Yangjin Park; Young-Wook Kim; Kwang Bo Park; Hong Suk Park; Young-Soo Do; Dong-Ik Kim
Journal:  J Korean Surg Soc       Date:  2012-05-29

10.  Critical limb ischemia.

Authors:  David L Dawson; Joseph L Mills
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.